BeOne Medicines AG
ONC
$335.17
$2.460.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 40.42% | 41.56% | 48.64% | 84.84% | 36.68% |
| Total Other Revenue | 111.86% | -- | -- | -- | -- |
| Total Revenue | 41.00% | 41.56% | 48.64% | 84.84% | 37.80% |
| Cost of Revenue | 15.28% | 19.17% | 32.07% | 54.59% | 104.69% |
| Gross Profit | 46.28% | 45.47% | 51.95% | 91.21% | 29.15% |
| SG&A Expenses | 16.21% | 21.23% | 7.45% | 31.39% | 29.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -105.26% | -- |
| Total Operating Expenses | 11.35% | 18.44% | 9.20% | 23.34% | 33.32% |
| Operating Income | 235.63% | 182.01% | 104.25% | 80.34% | -4.89% |
| Income Before Tax | 249.70% | 193.99% | 108.59% | 79.52% | -145.75% |
| Income Tax Expenses | -3.14% | -63.90% | 154.14% | 417.66% | 50.24% |
| Earnings from Continuing Operations | 202.88% | 178.34% | 100.51% | 58.27% | -160.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 202.88% | 178.34% | 100.51% | 58.27% | -160.81% |
| EBIT | 235.63% | 182.01% | 104.25% | 80.34% | -4.89% |
| EBITDA | 496.46% | 241.18% | 118.01% | 90.73% | 46.62% |
| EPS Basic | 198.86% | 175.71% | 100.49% | 59.13% | -160.42% |
| Normalized Basic EPS | 256.39% | 194.24% | 109.14% | 90.82% | -143.89% |
| EPS Diluted | 188.89% | 166.67% | 100.46% | 59.13% | -161.69% |
| Normalized Diluted EPS | 250.51% | 190.69% | 108.79% | 90.82% | -143.89% |
| Average Basic Shares Outstanding | 4.07% | 3.46% | 2.55% | 2.10% | 0.65% |
| Average Diluted Shares Outstanding | 8.13% | 7.51% | 6.62% | 2.10% | 0.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |